Craig Thompson Cerevance CEO

Third time’s the charm: Cere­vance’s Se­ries B ex­pands again

CNS-fo­cused Cere­vance ex­pand­ed its Se­ries B for the sec­ond time since 2020, reel­ing in an­oth­er $51 mil­lion to bankroll two Phase II clin­i­cal tri­als and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.